Alpha Cognition Inc. (ACOGF) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Vancouver, BC, 加拿大. 现任CEO为 Michael E. McFadden.
ACOGF 拥有 IPO日期为 2021-06-28, 在 Other OTC, 市值为 $35.66M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
